Method for producing a drug delivery system
Inventors
Schneeberger, Achim • Kühne, Klaus • KERSCHBAUMER, Helmut • VASIC, Srdan
Assignees
Exentis Knowldege GmbH • Laxxon Medical AG • Exentis Knowledge GmbH
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12290606-B2
Publication Date
2025-05-06
Expiration Date
Abstract
The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.
Core Innovation
The invention relates to a method for producing a drug delivery system by screen-printing a base paste and then curing the base paste. A first paste is then screen-printed separate to the base paste and cured, where the first paste comprises a therapeutically effective amount of a first active pharmaceutical ingredient, API. The base paste and the first paste are soluble in body fluids so that the resulting drug delivery system is soluble in body fluids.
In the resulting drug delivery system, the pastes are arranged by screen-printing so that the first paste is inhomogeneously arranged in the base paste. The base paste is provided as a three-dimensional body, and the separate first paste is inhomogeneously arranged throughout the base paste along the three dimensions. This inhomogeneous arrangement configures a concentration of the first API that varies throughout the drug delivery system.
The screen-printing is further set so that a transition from an area with a high API concentration to an area with a low API concentration is smooth. The concentration profile is such that, upon application of the drug delivery system, the release of the first API occurs at a varying rate. The first API is a CNS agent.
Claims Coverage
The independent claim covers five central inventive features: separate curing of a base paste and an API-containing first paste, solubility in body fluids, inhomogeneous three-dimensional arrangement of the first paste in the base paste, spatially varying API concentration with a smooth transition, and varying-rate release upon application, with the first API being a CNS agent.
Separate screen-printing and curing of base paste and API first paste
Screen-printing a base paste; curing the base paste; screen-printing a first paste separate to the base paste; curing the first paste; where the first paste comprises a therapeutically effective amount of a first active pharmaceutical ingredient, API.
Soluble pastes for a body-fluids-soluble drug delivery system
The base paste and the first paste are soluble in body fluids such that the resulting drug delivery system is soluble in body fluids.
Three-dimensional inhomogeneous arrangement of the API-containing first paste
The pastes are screen-printed such that in the resulting drug delivery system the first paste is inhomogeneously arranged in the base paste; and the base paste is provided as a three-dimensional body and the separate first paste is inhomogeneously arranged throughout the base paste along the three dimensions.
Spatially varying API concentration with smooth high-to-low transition
The pastes are screen-printed such that the concentration of the first API varies throughout the drug delivery system; and a transition from an area in the drug delivery system with a high API concentration to an area in the drug delivery system with a low API concentration is smooth.
Varying-rate API release upon application of an inhomogeneous concentration profile
The concentration profile of the first API is such that upon application of the drug delivery system the release of the first API occurs at a varying rate; where the first API is a CNS agent.
Overall claim coverage is anchored in a production method that uses separate screen-printing and curing of a soluble base paste and a soluble API-containing first paste, then creates a three-dimensional inhomogeneous arrangement that produces a spatially varying first-API concentration with a smooth high-to-low transition, resulting in varying-rate release upon application; the first API is a CNS agent.
Stated Advantages
Enables release of the first API at a varying rate upon application based on a smooth transition between high- and low-concentration areas.
Provides a resulting drug delivery system that is soluble in body fluids.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?